Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair in Chronic Sinusitis with Positive Allergen Test
NCT00117611Phase 4Completed
- Sponsor
- University of Chicago
- Start
- Jul 2005
- Primary completion
- May 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of omalizumab in sinusitis, sponsored by University of Chicago. Primary endpoint: Mucosal thickness on CT scan at 6 months. Started Jul 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
sinusitis
Beyond the preview
Go deeper on NCT00117611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117611.